A novel candidate tumor suppressor gene, TTC4, on chromosome 1p31 has been described recently. Since aberrations in this region have been detected in malignant melanoma, we investigated DNA of paranembedded sections from 16 typical naevi, 19 atypical naevi, 32 primary melanomas (15 super®cial spreading melanomas, 17 nodular melanomas) and 25 metastases and DNA from four melanoma cell lines by PCR and direct sequencing analysis for mutations in all exons of TTC4. Tumors comprised a wide range of thickness (Breslow index) and Clark levels. No mutations could be detected in typical or atypical naevi, but we found seven dierent point mutations in the tumor samples, six of them causing an amino acid change. Ten melanoma samples belonging to nine patients showed one or more of these mutations. In detail, in six of 25 metastases, in two of 17 nodular melanomas and in two of 15 super®cial spreading melanomas point mutations could be detected. In two cell lines, a loss of a whole exon could be demonstrated and in one cell line we found a point mutation. In addition, three polymorphisms were found. Our ®ndings indicate that TTC4 may participate in the pathogenesis of malignant melanomas of the skin.
A novel candidate tumor suppressor gene, TTC4, on chromosome 1p31 has been described recently. Since aberrations in this region have been detected in malignant melanoma, we investigated DNA of paranembedded sections from 16 typical naevi, 19 atypical naevi, 32 primary melanomas (15 super®cial spreading melanomas, 17 nodular melanomas) and 25 metastases and DNA from four melanoma cell lines by PCR and direct sequencing analysis for mutations in all exons of TTC4. Tumors comprised a wide range of thickness (Breslow index) and Clark levels. No mutations could be detected in typical or atypical naevi, but we found seven dierent point mutations in the tumor samples, six of them causing an amino acid change. Ten melanoma samples belonging to nine patients showed one or more of these mutations. In detail, in six of 25 metastases, in two of 17 nodular melanomas and in two of 15 super®cial spreading melanomas point mutations could be detected. In two cell lines, a loss of a whole exon could be demonstrated and in one cell line we found a point mutation. In addition, three polymorphisms were found. Our ®ndings indicate that TTC4 may participate in the pathogenesis of malignant melanomas of the skin. Oncogene (2000) 19, 5817 ± 5820.
Keywords: TTC4; malignant melanoma; sequencing analysis Deletions of the short arm of chromosome 1 are among the most frequent aberrations in many solid tumors including neuroblastoma, breast cancer and malignant melanoma of the skin (Heim and Mitelman, 1995) . Although Dracopoli et al. (1989) demonstrated a deletion especially in the subterminal region of 1p by loss of heterocygosity analysis (LOH), cytogenetic analysis and comparative genomic hybridization analysis (CGH) found chromosomal loss in all parts of 1p in malignant melanoma (Thompson et al., 1995; Wiltshire et al., 1995) . In a recent¯uorescence in situ hybridization (FISH) study with YAC DNA probes, we were able to demonstrate deletions not only in 1p36, but also in 1p31 (Poetsch et al., 1999) . Lately, a novel human gene with the tetratricopeptide repeat (TPR) has been mapped in this part of the short arm of chromosome 1 and named TTC4 (Su et al., 1999) . A variety of other genes belong to this family and dierent functions have been assigned to genes with TPR motifs (Blatch and LaÈ ssle, 1999) . The members of the human TPR motif gene family include cochaperones like IEFSSP3521 (Honore et al., 1992) or FKBPRr38 (Lam et al., 1995) , genes with protein transport functions like PXR1 (Fransen et al., 1995) , genes with importance in phosphate turnover like PP5 (Chen et al., 1994) , and a gene with cell cycle control functions (Schrick et al., 1995) . Very recently, additional genes with TPR motifs have been found which demonstrate interactions with heat shock proteins or are necessary for the formation of the phagocyte NADPH oxidase (Ballinger et al., 1999; Koga et al., 1999; Zhang and Grishin, 1999) . Evidence for an involvement of TPR motif genes in neoplasia is more dicult. Another member of the TPR motif family (Tg737) seems to be involved in liver tumorigenesis (Isfort et al., 1997) . Tg737 showed deletions or rearrangements in 40% of carcinogen-induced liver tumors in rats and Isfort et al. (1997) were able to detect similar changes in human liver, kidney and pancreas tumors. In addition, they demonstrated a suppression of the tumor forming ability in nude mice by overexpressing Tg737 in cells otherwise lacking this gene. These facts and the localization of TTC4 within a region of interest in certain cancer initiated our study of DNA from paran embedded tissue and corresponding constitutional DNA from 16 typical naevi, 19 atypical naevi, 15 super®cial spreading melanomas, 17 nodular malignant melanomas and 25 metastatic melanomas from 48 non-selected melanoma patients comprising a wide range of thickness (Breslow index) and Clark levels which were staged and classi®ed as stated elsewhere (Poetsch et al., 1998) . Six patients had multiple metastatic lesions. DNA isolation from paran embedded tissue was performed as described before (Poetsch et al., 2000) . In addition, the four melanoma cell lines M19, DX3 (Albino et al., 1981) , MEWO (Siracki et al., 1982) , and LT5.1 have been included in this study. Using PCR and direct sequencing analysis we screened for mutations in exons 1 through 10 of TTC4. In the constitutional DNA of all melanoma patients, in all 35 naevi and in all 57 investigated melanoma samples the 10 exons of TTC4 could be ampli®ed; this is, we did not ®nd any homozygous deletions of the complete gene of a whole exon in these samples, but in the cell line LT5.1 exon 1 and in M19 exon 3 could not be ampli®ed, while the remaining exons are intact.
No mutations could be found in any of the typical or atypical naevi, but seven point mutations could be detected among our tumor samples (Table 1) , which did not appear in the constitutional DNA isolated from the blood of the patients. Therefore, these aberrations prove to be real mutations and not rare polymorphisms. Six of these mutations led to an amino acid change. They were distributed over the exons 1 ± 6 and appeared with one exception only once. An A?C change in exon 3 could be demonstrated in ®ve dierent tumor samples belonging to four unrelated patients (Figure 1a ). In addition, in the cell line MEWO a point mutation in exon 6 (codon 201) could be detected, which resulted in a change from glutamine to alanine.
The mutations appeared in six metastases (24%), two nodular melanomas (12%), and two super®cial spreading melanomas (13%), with one metastasis showing two dierent mutations. In all metastases and in one nodular melanoma (NM47) only the mutated allele was present, indicating loss of heterozygosity in this region. Two of these tumor samples (MM11, MM14) belonging to one patient displayed a deletion in 1p31 in our prior FISH study (Poetsch et al., 1999) , in two melanomas no such deletion could be detected, the other six tumor samples have not been included in the FISH study. At the moment we can not show a correlation between Breslow index or Clark level and the mutations. In addition, no relation between the occurrence of multiple metastatic lesions or survival after diagnosis and a mutation in TTC4 could be demonstrated which might be due to the limited case number. However, the mutations occurred more often in metastasis and nodular melanomas, known to harbor a worse prognosis. We could not analyse the expression of TTC4 mRNA in our tumor samples due to the fact that we investigated samples of paran embedded material which besides having dierently ®xed comprised archive material ± up to 10 years old ± where RNA is mostly degraded. In addition, no antibody for the TTC4 protein was available for us thus restricting our analysis to the DNA of this gene.
Two of our seven mutations may have greater importance than the others: the A?C change in codon 77 occurring in ®ve tumor samples of four unrelated patients results in an amino acid change from glutamic acid to alanine (Figure 1a) . It lies in the near neighborhood of the ®rst potential TPR repeat motif and its appearance in three metastases, one SSM, and one NM hints at a possible signi®cance of this mutation in melanoma. Since the chemical dierence between glutamic acid and alanine is rather great, this mutation will possibly lead to a conformation change of the protein implicating a reduction or loss of protein function. The potential importance of a second mutation ± the C?T change in codon 135 ± derived from its location in the gene: it resides in the middle of the second potential TRP repeat (Figure 1b ). This mutation results in the amino acid phenylalanine instead of serine and occurred only in the metastasis MM11. Phenylalanine with its hydrophobic structure in comparison to the hydrophilic serine may disturb folding of the TRP repeat thus preventing the active centrum of the protein from right function.
In addition to the above mentioned mutations we found a variety of alterations referring to the published sequence (Su et al., 1999) in tumor DNA and the corresponding constitutional DNA. Three of them could be clearly de®ned as polymorphism (in exon 2, exon 5, and intron 8), since they occurred in normal controls, in the naevi, and in the melanoma patients with dierent heterozygosity rates ( Table 2 ). The most Indicating deletions in 1p31 in a prior FISH study (Poetsch et al., 1999) ; n.d. -not determined; c SSM, super®cial spreading melanoma; NM, nodular melanoma; MM, metastatic melanoma; d DOD, died of disease; NED, no evidence of disease; AWD, alive with disease The other two polymorphisms were a silent point mutation in exon 5 and a 5 bp insertion in intron 8. Moreover, three alterations to the published sequence (Su et al., 1999) were found in all our tumor samples and corresponding germ line DNAs as well as in the naevi and in all 50 normal controls from the same geographical region (data not shown): a T?A change at position 494 (codon 165, resulting in Ile?Lys), a T?C change at position 936 (codon 312, silent) and an insertion of one C at position 964.1. The last alteration results in a dierent amino acid sequence after codon 320 (cysteine), which is 31 amino acids longer than the published sequence (Su et al., 1999) (Figure 2 shows a comparison). However, this does not change the potential TPR repeat motifs. Since in our investigation only patients from a de®ned region in northeast Germany have been included, whereas Su et al. (1999) worked with breast cancer cell lines from other sources, these three alterations also might be polymorphisms with dierent occurrence. Since three out of four cell lines tested showed an alteration of TTC4 and mutations are distributed over primary tumors and metastases in about the same manner as the deletions found in our FISH study (Poetsch et al., 1999) , TTC4 may have an importance for the establishment of malignant melanoma. But due to the small number of cases, we do not feel comfortable speculating, if its relevance lies in the onset or the progression of melanoma. N Hibberts for providing the cell line M19. We thank S Seefeldt, M Maschke, and M Richter for excellent technical assistance.
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Figure 1 TTC4 sequence pro®les in melanoma samples. All nucleotide positions are based on the cDNA sequence in the EMBL database under Accession No. AF073887_2. Mutation analysis of the 10 exons of the TTC4 gene was carried out with the primers described by Su et al. (2000) by PCR and sequencing analysis with the ABI 310 DNA sequencer (Perkin Elmer). Each polymorphism or mutation was veri®ed by a second sequencing reaction of an independent ampli®cation product. (a) Sequence pro®le of a part of intron 2 and a part of exon 3 (nucleotides 230 ± 279) of the wild-type (above) and NM42 (below) with the arrow indicating the A?C change at position 230. (b) Sequence pro®le of a part of intron 3 and a part of exon 4 (nucleotides 393 ± 440) of the wild-type (above) and MM11 (below) with the arrow indicating the C?T change at position 404 Figure 2 Comparison between the published sequence of TTC4 (EMBL accession number AF073887) and deduced amino acid sequence (Su et al., 1999) and the DNA sequence (underlined) and deduced amino acid sequence (bold type) resulted by the insertion of a C at position 964.1 (indicated by an asterisk) starting with codon 320
